Malignant mesothelioma is associated with exposure to asbestos, as documented in the certified disease definition. The condition is classified as multifactorial in origin, reflecting a combination of environmental exposure and genetic susceptibility factors. The gene WT1, located on chromosome 11, is certified as associated with malignant mesothelioma in this packet; no ClinGen validity classification is provided for this gene-disease association in the certified data. Additional genetic associations are not certified in this packet's known_genes field.

Malignant mesothelioma arises from mesothelial cells of the pleura or peritoneum and is classified as a malignant neoplasm. The condition is associated with asbestos exposure as documented in the certified definition. Specific diagnostic methods are not certified in this packet beyond the disease definition and anatomic classification.

FDA-approved treatment coverage for malignant mesothelioma is absent or not certified in this packet. Investigational research activity is substantial, as reflected in the certified clinical trial landscape described in the Research section.

Certified prognosis information is not available in this packet. Malignant mesothelioma is classified as a malignant neoplasm of the pleura or peritoneum.

Malignant mesothelioma has active clinical research activity. The packet certifies 82 active clinical trials. Among the certified trial records: NCT05001880 (Phase 2, Recruiting) examines chemotherapy with or without immunotherapy for peritoneal mesothelioma, sponsored by NCI, projected to complete August 2026. NCT02414269 (Phase 1, Active Not Recruiting) studies autologous T cells genetically engineered to target the mesothelin antigen in malignant pleural disease, sponsored by Memorial Sloan Kettering Cancer Center, projected to complete April 2027. NCT06057935 (Phase 2, Recruiting) examines additional chemotherapy after surgery for malignant peritoneal mesothelioma, sponsored by Memorial Sloan Kettering Cancer Center, projected to complete September 2028. NCT07277413 (Phase 1, Recruiting) studies IDE892 as monotherapy and in combination in MTAP-deleted advanced solid tumors, sponsored by IDEAYA Biosciences, projected to complete April 2028. NCT03228537 (Phase 1, Active Not Recruiting) examines atezolizumab in combination with chemotherapy and surgery in Stage I-III pleural malignant mesothelioma, sponsored by NCI, projected to complete September 2026. NCT03830229 (No phase specified, Recruiting) is a long-term follow-up study of mesothelioma patients and individuals with germline predisposition mutations, sponsored by NCI, projected to complete December 2034. The research landscape digest documents 448 classified publications; review and meta-analysis publications are the dominant type, with biomarker and gene therapy publication activity also documented.